文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

解读肝纤维化-肝细胞癌轴:从机制到治疗机遇

Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities.

作者信息

Lin Anqi, Xiong Minying, Tang Bufu, Jiang Aimin, Shen Junyi, Liu Zaoqu, Cheng Quan, Zhang Jian, Luo Peng

机构信息

Jiangnan University Smart Healthcare Joint Laboratory, Donghai County People's Hospital (Kangda College of Nanjing Medical University), Lianyungang, 222000, Jiangsu Province, China.

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

出版信息

Hepatol Int. 2025 Jul 1. doi: 10.1007/s12072-025-10838-y.


DOI:10.1007/s12072-025-10838-y
PMID:40588713
Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent malignant neoplasm globally and represents the third-leading cause of cancer-associated mortality worldwide. Epidemiological data indicate that 80-90% of HCC cases demonstrate documented progression from hepatic fibrosis or cirrhosis. This fibrotic-carcinogenic continuum represents a complex multistep pathological cascade, with mechanistic insights being progressively revealed through contemporary investigations. OBJECTIVE: This review systematically elucidates the mechanistic contributions of dysregulated signaling pathways and immune microenvironmental remodeling during hepatic fibrocarcinogenesis. METHODS: A systematic online screening protocol was implemented across multiple biomedical databases to curate relevant studies elucidating mechanisms underlying fibrosis-driven hepatocarcinogenesis. RESULTS: This work conducts a comprehensive pathophysiological analysis of hepatic fibrosis-HCC transition, including dysregulated cytokine networks, dynamic extracellular matrix (ECM) remodeling, epigenetic dysregulation, immune landscape reprogramming, persistent oxidative stress, and acquired mitochondrial dysfunction. The analysis comprehensively evaluates widely utilized experimental models in fibrotic liver carcinogenesis research, while critically assessing emerging biomarkers and mechanism-based therapeutic targets. CONCLUSION: This synthesis lays conceptual foundations for advancing translational research on biomarker discovery and precision therapeutics, while offering substantive guidance for developing mechanistically informed strategies to optimize clinical outcomes in hepatic fibrosis and HCC management.

摘要

背景:肝细胞癌(HCC)是全球第六大常见恶性肿瘤,也是全球癌症相关死亡的第三大原因。流行病学数据表明,80-90%的HCC病例显示有从肝纤维化或肝硬化发展而来的记录。这种纤维化-致癌连续体代表了一个复杂的多步骤病理级联反应,通过当代研究,其机制见解正逐渐被揭示。 目的:本综述系统地阐明了肝纤维致癌过程中信号通路失调和免疫微环境重塑的机制作用。 方法:在多个生物医学数据库中实施了系统的在线筛选方案,以整理阐明纤维化驱动肝癌发生机制的相关研究。 结果:本研究对肝纤维化向HCC转变进行了全面的病理生理分析,包括细胞因子网络失调、动态细胞外基质(ECM)重塑、表观遗传失调、免疫格局重编程、持续氧化应激和获得性线粒体功能障碍。该分析全面评估了在纤维化肝癌发生研究中广泛使用的实验模型,同时严格评估了新兴的生物标志物和基于机制的治疗靶点。 结论:本综述为推进生物标志物发现和精准治疗的转化研究奠定了概念基础,同时为制定基于机制的策略以优化肝纤维化和HCC管理的临床结果提供了实质性指导。

相似文献

[1]
Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities.

Hepatol Int. 2025-7-1

[2]
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.

Cancer Lett. 2021-8-10

[3]
Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Metabolism. 2016-8

[4]
Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.

J Exp Clin Cancer Res. 2025-7-15

[5]
Progression to fibrosis and hepatocellular carcinoma in DEN CCl liver mice, is associated with macrophage and striking regulatory T cells infiltration.

Front Immunol. 2025-7-8

[6]
Ganoderic acid A regulates CSF1R to reprogram tumor-associated macrophages for immune therapy of hepatocellular carcinoma.

Int Immunopharmacol. 2025-8-28

[7]
Comprehensive two-dimensional primary hepatic stellate cell (HSC) membrane chromatography-based screening of anti-fibrotic components from Schisandra chinensis (Turcz.) Baill. and mechanistic insights into gomisin N against liver fibrosis.

J Ethnopharmacol. 2025-7-24

[8]
Oroxyloside inhibits liver fibrosis and hepatocarcinogenesis dependent on hepatocyte-specific knockout of Atg5.

Phytomedicine. 2025-7-6

[9]
Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery.

Cancer Res. 2024-8-15

[10]
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.

Health Technol Assess. 2023-12

引用本文的文献

[1]
Prognostic Significance of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Liver Transplantation for Hepatocellular Carcinoma.

Curr Oncol. 2025-8-16

本文引用的文献

[1]
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

J Hematol Oncol. 2025-1-13

[2]
Targeting p97/Valosin-Containing Protein Promotes Hepatic Stellate Cell Senescence and Mitigates Liver Fibrosis.

DNA Cell Biol. 2025

[3]
Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models.

Front Immunol. 2024

[4]
Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.

Int J Biol Sci. 2024

[5]
Impact of heterogeneity in liver matrix and intrahepatic cells on the progression of hepatic fibrosis.

Tissue Cell. 2024-12

[6]
Recent Advances in the Glycolytic Processes Linked to Tumor Metastasis.

Curr Mol Pharmacol. 2024

[7]
Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation.

Curr Mol Pharmacol. 2024

[8]
Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts.

Mol Cancer. 2024-8-2

[9]
Renal cancer: signaling pathways and advances in targeted therapies.

MedComm (2020). 2024-8-1

[10]
The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics.

Cancer Discov. 2024-8-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索